A third spinal muscular atrophy treatment is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam. The medicine offers at-home dosing for patients, potentially giving it an edge versus the competition during the COVID-19 pandemic. Another potential edge? Price. Genentech set Evrysdi’s list price at up to $340,000 per year, depending on a patient’s weight. For some younger patients, the price could be under $100,000, a spokesman said. “We carefully considered a number of factors, including input from the SMA community, and took a long-term, thoughtful approach in determining the price of Evrysdi to help ensure those who are prescribed can access this first and only at-home SMA treatment, shown to be safe and effective across a wide range of ages and SMA types in our clinical trials,” he added
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!